KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

被引：0
|
作者：
F Loupakis
A Ruzzo
C Cremolini
B Vincenzi
L Salvatore
D Santini
G Masi
I Stasi
E Canestrari
E Rulli
I Floriani
K Bencardino
N Galluccio
V Catalano
G Tonini
M Magnani
G Fontanini
F Basolo
A Falcone
F Graziano
机构：
[1] Unit of Medical Oncology 2,Istituto Toscano Tumori and Department of Oncology
[2] Azienda-Ospedaliero Universitaria Pisana,Department of Biomolecular Sciences
[3] Transplantes and New Technologies in Medicine,Division of Pathology, Department of Surgery
[4] University of Pisa,undefined
[5] Section of Biochemistry and Molecular Biology “G. Fornaini”,undefined
[6] University of Urbino,undefined
[7] Unit of Medical Oncology,undefined
[8] University Campus Biomedico,undefined
[9] Via Alvaro del Portillo 200 – 00128 Rome,undefined
[10] Italy,undefined
[11] Mario Negri Institute for Pharmacological Research,undefined
[12] Via La Masa 19 – 20156 Milan,undefined
[13] Italy,undefined
[14] Unit of Medical Oncology,undefined
[15] San Raffaele Scientific Institute,undefined
[16] Via Olgettina 60 – 20132 Milan,undefined
[17] Italy,undefined
[18] Unit of Medical Oncology,undefined
[19] Hospital of Pesaro,undefined
[20] Via Lombroso 1 – 61100 Pesaro,undefined
[21] Italy,undefined
[22] University of Pisa,undefined
[23] Istituto Toscano Tumori,undefined
[24] Via Roma 67 – Pisa,undefined
[25] Italy,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：715 / 721
页数：6
相关论文
共 50 条
  • [21] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [22] KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (7): : 365 - 365
  • [23] Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
    Yu Imamura
    Paul Lochhead
    Mai Yamauchi
    Aya Kuchiba
    Zhi Rong Qian
    Xiaoyun Liao
    Reiko Nishihara
    Seungyoun Jung
    Kana Wu
    Katsuhiko Nosho
    Yaoyu E Wang
    Shouyong Peng
    Adam J Bass
    Kevin M Haigis
    Jeffrey A Meyerhardt
    Andrew T Chan
    Charles S Fuchs
    Shuji Ogino
    Molecular Cancer, 13
  • [24] Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
    Imamura, Yu
    Lochhead, Paul
    Yamauchi, Mai
    Kuchiba, Aya
    Qian, Zhi Rong
    Liao, Xiaoyun
    Nishihara, Reiko
    Jung, Seungyoun
    Wu, Kana
    Nosho, Katsuhiko
    Wang, Yaoyu E.
    Peng, Shouyong
    Bass, Adam J.
    Haigis, Kevin M.
    Meyerhardt, Jeffrey A.
    Chan, Andrew T.
    Fuchs, Charles S.
    Ogino, Shuji
    MOLECULAR CANCER, 2014, 13
  • [25] Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS
    Hong, Yong Sang
    Kim, Hwa Jung
    Park, Seong Joon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (04) : 473 - 480
  • [26] Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer
    Kwak, Min S.
    Cha, Jae M.
    Cho, Young H.
    Kim, Sang H.
    Yoon, Jin Y.
    Jeon, Jung W.
    Shin, Hyun P.
    Joo, Kwang R.
    Lee, Joung I.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 (05) : 431 - 436
  • [27] Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Loupakis, F.
    Cremolini, C.
    Perrone, G.
    Stasi, I.
    Salvatore, L.
    Vincenzi, B.
    Ruzzo, A.
    Ronzoni, M.
    Bencardino, K.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer
    Hoyle, Martin
    Peters, Jaime
    Crathorne, Louise
    Jones-Hughes, Tracey
    Cooper, Chris
    Napier, Mark
    Hyde, Chris
    VALUE IN HEALTH, 2013, 16 (02) : 288 - 296
  • [29] Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value
    Ahn, Hong-Min
    Kim, Duck-Woo
    Oh, Hyeon Jeong
    Kim, Hyung Kyung
    Lee, Hye Seung
    Lee, Tae Gyun
    Shin, Hye-Rim
    Yang, In Jun
    Lee, Jeehye
    Suh, Jung Wook
    Oh, Heung-Kwon
    Kang, Sung-Bum
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (32) : 4883 - 4899
  • [30] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
    ELez, E.
    Kocakova, I.
    Hoehler, T.
    Martens, U. M.
    Bokemeyer, C.
    Van Cutsem, E.
    Melichar, B.
    Smakal, M.
    Csoszi, T.
    Topuzov, E.
    Orlova, R.
    Tjulandin, S.
    Rivera, F.
    Straub, J.
    Bruns, R.
    Quaratino, S.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 132 - 140
12345